Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Views - The company demonstrated resilience in operations despite industry pressures, with a focus on health consumer products and prescription drugs showing growth [2]. - The company is positioned as a leading player in the OTC market for gastrointestinal products in China, with expectations for steady growth through both organic and external means [1]. - The company has implemented cost optimization strategies that have led to improved profitability and stable cash flow [3]. Summary by Sections Financial Performance - For the first half of 2025, the company reported revenues of 2.14 billion RMB, a decrease of 6% year-on-year, while net profit attributable to shareholders was 520 million RMB, an increase of 6% year-on-year [1]. - The second quarter of 2025 saw revenues of 960 million RMB, a decline of 4% year-on-year, but net profit attributable to shareholders increased by 6% to 240 million RMB [1]. - The gross margin for the first half of 2025 was 66.6%, down 2.4 percentage points year-on-year, primarily due to a decrease in the proportion of high-margin OTC business [3]. Business Segments - The OTC segment faced challenges with revenues of 1.55 billion RMB, down 10% year-on-year, while health consumer products grew by 17% to 230 million RMB, and prescription drugs increased by 7% to 360 million RMB [2]. - The company has strengthened its online marketing channels and brand building, which contributed to the growth in health consumer products [2]. Dividend Policy - The company announced a cash dividend of 0.5 RMB per share for the first half of 2025, representing 60.78% of the net profit attributable to shareholders [1][4]. - The company plans to maintain a high dividend payout ratio during the 14th Five-Year Plan period, emphasizing its commitment to shareholder returns [4]. Future Outlook - The company forecasts net profits attributable to shareholders of 897 million RMB, 1.015 billion RMB, and 1.145 billion RMB for 2025, 2026, and 2027, respectively, reflecting growth rates of 14%, 13%, and 13% year-on-year [5]. - The target price for the company's stock is set at 29.96 RMB, based on a 21x PE ratio for 2025 [5].

Investment Rating - The report assigns a "Buy" rating to the company [10]. Core Insights - Yuehai Investment is a Guangdong state-owned enterprise with a strong portfolio in water supply to Hong Kong, holding a 30-year concession for the Dongshen Water Supply Project, which accounts for 70%-80% of local freshwater usage. The company is expected to enter a stable dividend phase by 2025, with an estimated dividend yield of 6.77% [3][6]. Summary by Sections Company Overview - Yuehai Investment is primarily focused on water resources, with the Guangdong provincial government holding a 58.27% stake. The company operates five main business segments, with the water resources segment contributing 81% to the overall pre-tax profit. The Dongshen Water Supply Project is the core asset, providing stable cash flow [6][16]. Water Resources - The Dongshen Water Supply Project has a supply capacity of 2.423 billion cubic meters annually, supplying 70%-80% of Hong Kong's freshwater and over 50% of Shenzhen's water. The project is expected to generate 39% of its total supply to Hong Kong in 2024, contributing 81% to the project's total revenue [7][36]. Other Water Projects - Other water resource projects have entered a stable operational phase, with a design capacity of 5.895 billion tons/year for water supply and 1.221 billion tons/year for sewage treatment. Revenue from construction has declined significantly, indicating a shift to stable operations [8][30]. Other Business Segments - The performance of other business segments has stabilized after the removal of factors causing volatility. The contributions to pre-tax profit from various segments are 81% from water resources, 10% from property investment, and smaller percentages from other sectors [9][23]. Financial Analysis & Profit Forecast - The company is projected to achieve a sustainable net profit of HKD 4.1 billion in 2024, with a debt ratio of 30.9% by the end of 2024. The dividend payout ratio is expected to remain at 65% for 2023-2024, with forecasted net profits of HKD 4.54 billion, HKD 4.75 billion, and HKD 4.83 billion for 2025-2027, respectively [10][28].